I-Mab (US44975P1030)

Overview

I-Mab is a forward-thinking clinical stage biopharmaceutical company, mainly focusing on the discovery, development, and commercialization of novel biologics in the treatment areas of cancer and autoimmune disorders. Established in 2014 and with its headquarters rooted in Shanghai, People's Republic of China, the company propels medical advancements through its prolific pipeline and strategic collaborations. Leveraging its expertise in biotechnology, I-Mab has formed strategic partnerships with key players in the pharmaceutical and biotechnology sectors, including PT Kalbe Genexine Biologics, AbbVie Ireland Unlimited Company, Jumpcan Pharmaceutical Group, Sinopharm Group Co. Ltd., and Roche Diagnostics. These collaborations aim to enhance the company's research capabilities and expedite the development of its potential therapies.

Products and Services

• Felzartamab (CD38 antibody):

  Currently in Phase 1b/2a of clinical trials, Felzartamab is being developed as a potential treatment for patients suffering from membranous nephropathy, focusing on harnessing the body's immune system to fight off this kidney ailment.

• Eftansomatropin alfa (long-acting growth hormone):

  This is a bioengineered long-acting growth hormone designed to treat pediatric growth hormone deficiency. Having completed Phase 3 clinical trials, Eftansomatropin alfa stands at the brink of revolutionizing treatment for children with growth issues.

• Efineptakin alfa (recombinant human IL-7):

  In Phase 2 clinical development, Efineptakin alfa targets cancer treatment-related lymphopenia and cancer immunotherapy. It represents I-Mab's commitment to enhancing cancer patients’ immune responses and improving treatment outcomes.

• Lemzoparlimab (CD47 monoclonal antibody):

  Having completed a Phase 2 clinical trial, Lemzoparlimab, a CD47 monoclonal antibody, is a potential game-changer in the way cancer is treated, heralding a new era of immunotherapy with its ability to help the immune system recognize and eliminate cancer cells.

• TJ210 (monoclonal antibody against human C5aR1):

  This investigational antibody is in Phase 1 clinical development for treating cancers and autoimmune diseases, evidencing I-Mab’s diversified approach in targeting complex diseases through specialized pathways.

• Uliledlimab (CD73 antibody):

  Currently in Phase 2 clinical trials, Uliledlimab aims to treat solid tumors and oncology through its novel mechanism of targeting the CD73 pathway, a new frontier in cancer immunotherapy.

• TJ-L14B (PD-L1-based tumor-dependent T-cell engager):

  A next-generation approach for treating solid cancers, TJ-L14B leverages the power of the body's T cells to specifically target and attack cancer cells, embodying the future of personalized cancer therapy.

• Givastomig (tumor-dependent T cell engager):

  Focused on gastric and other cancers, Givastomig represents an innovative biotherapeutic approach to engage the body’s immune system in recognizing and fighting tumor cells.

• TJ-L1IF (PD-L1/IFN-a antibody-cytokine fusion protein):

  Designed for PD(L)-1 resistant tumors, TJ-L1IF combines the targeted action of PD-L1 inhibition with the immune-stimulating effects of IFN-a, offering a novel therapeutic strategy for hard-to-treat cancers.

• TJ-C64B (bispecific antibody):

  This bispecific antibody targets ovarian and other cancers by simultaneously engaging two distinct pathways. TJ-C64B exemplifies I-Mab’s ambition to tackle cancer with multi-faceted strategies.